Douglas Lazarus

BioClinica (United States) — United States

Engineering · Physical Sciences

21h-index3.3kcitations58works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Nanoplatforms for cancer theranostics(13), Cancer, Hypoxia, and Metabolism(12), Growth Hormone and Insulin-like Growth Factors(8), Nanoparticle-Based Drug Delivery(7), Cancer Research and Treatments(5)

Publications57 total

Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy
Molecular Imaging and Biology·2026Open Access
Abstract 548: The microRNA-10b targeted therapeutic, TTX-MC138, is effective in preclinical pancreatic adenocarcinoma
Cancer Research·2023· 7 cited
Supplemental Figures 1-5 and Methods from Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
2023Open Access
Data from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
2023Open Access
Data from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
2023Open Access
Supplemental Figures 1-5 and Methods from Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
2023Open Access
Supplemental Figures S1-S6 from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
2023Open Access
Supplemental Figures S1-S6 from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
2023Open Access
Supplemental Methods from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
2023Open Access
Data from Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
2023Open Access
Data from Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
2023Open Access
Supplemental Methods from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
2023Open Access
A Novel Allogeneic Cell Therapy That Targets Pathogenic Autoantibodies for the Treatment of Immune Thrombocytopenia
Blood·2021· 1 cited
Discovery of a Novel Cabazitaxel Nanoparticle–Drug Conjugate (CRLX522) with Improved Pharmacokinetic Properties and Anticancer Effects Using a β-Cyclodextrin–PEG Copolymer Based Delivery Platform
Journal of Medicinal Chemistry·2019· 9 cited
Abstract 3209: CRLX101, an investigational nanoparticle-drug conjugate of camptothecin, demonstrates synergy with immunotherapy agents in preclinical models
Cancer Research·2016· 5 cited
Abstract 1345: Tumor selective localization of CRLX101, an investigational nanoparticle-drug conjugate of camptothecin
Cancer Research·2016
Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
Cancer Research·2016· 69 cited
Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical
Molecular Pharmaceutics·2016· 26 cited
Abstract B176: In vitro and in vivo studies demonstrating sustained drug release for multiple anticancer payloads and improved anticancer effects of a cabazitaxel β-cyclodextrin-PEG copolymer-based nanoparticle-drug conjugate (NDC)
Molecular Cancer Therapeutics·2015· 1 cited
Abstract B37: Selective tumor localization of CRLX101, a novel nanoparticle-drug conjugate
Molecular Cancer Therapeutics·2015· 2 cited
page 1 of 3Next →

Frequent Co-authors

Scott Eliasof(22), Christian Peters(18), Lyle L. Moldawer(12), Elizabeth Pham(10), Robert S. Kerbel(10), Christina R. Lee(9), Shan Man(9), Lata Jayaraman(8), Ellen Rohde(8), Melissa Yin(6), Donna M. Brown(6), F. Stuart Foster(6), S F Lowry(6), Ping Xu(6), Roy I. Case(5), Annabelle Chow(5), Sujan Kabir(5), Jungyeon Hwang(4), Edward G. Garmey(4), Carolyn Krasner(4)